20/05/2026
Clinical validation is not an end; it is a powerful beginning.
Collaboration becomes stronger once a technology has crossed the validation threshold. It creates a solid foundation for the conversations shaping how a drug delivery platform can expand, where it can travel next and how it can empower new programs.
Our position around this role is now even stronger: to carry Sagitta® into clinical and business development and to support co-development projects built on the versatility of our platforms. The successful completion of Phase 1 for RS-0139, powered by Sagitta®, marked an important step not only for a lead program, but also for the broader potential of our technology.
Today, we see is more than a milestone worth recognizing. It is also a reminder that translation to clinic can become a starting point for new scientific and strategic possibilities.
w/ Prof. Rana Sanyal | Dr. Sena Nomak | Gulsah Nomak, MD